Telehealth-based controlled substance prescribing sits at the intersection of federal DEA rules, COVID-era flexibilities that keep getting extended, state NP scope of practice laws, and state-specific controlled substance restrictions — all of which have been in flux since 2020. For an NP practicing via telehealth, getting this wrong means prescribing outside your legal authority, which carries DEA enforcement risk, state board consequences, and potential criminal exposure.
This guide covers where things stand as of 2026, what you can and cannot prescribe via telehealth, and how to structure your practice to stay compliant.
Quick-scan summary
| Topic | 2026 status |
|---|---|
| Ryan Haight Act (baseline rule) | Still in effect — requires in-person visit before prescribing Schedule II–V via telehealth |
| COVID flexibility extensions | Fourth extension active through December 31, 2026 — in-person requirement waived for existing patients |
| DEA Special Registration | Proposed rule published January 2025; not yet finalized as of mid-2026 |
| Schedule II stimulants / opioids | Prescribing allowed via telehealth under 2026 extension for current patients |
| Schedule III–V controlled substances | Allowed via telehealth under extension, including audio-only in some cases |
| Buprenorphine/Suboxone | Special rules apply; audio-only permitted for opioid use disorder without in-person |
| State restrictions | Many states add restrictions beyond federal floor — check your state |
| New patients | No in-person requirement waived under 2026 extension (DEA has allowed telehealth prescribing for new patients under the extension) |
The Ryan Haight Act: the baseline you’re working around
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 established the default rule: a DEA-registered practitioner may prescribe controlled substances via telemedicine only after conducting at least one in-person medical evaluation of the patient. The Act was designed to prevent internet-based “pill mills” from prescribing Schedule II–V substances without ever seeing a patient.
Without any exception, the Ryan Haight Act would require every telehealth NP to have seen each patient in person before issuing any controlled substance prescription. That would make telehealth prescribing of ADHD medications, anxiety medications, sleep aids, or opioids essentially impossible for practices without a hybrid in-person/virtual model.
The Act does provide narrow statutory exceptions — including prescribing in a DEA-registered hospital or clinic, in emergencies, for patients receiving hospice care, and via a “telemedicine” modality defined under specific circumstances — but these exceptions are limited and not a practical workaround for most telehealth NPs.
The 2026 extension: what’s currently allowed
When the COVID-19 public health emergency (PHE) ended in May 2023, it raised the question of what would happen to DEA’s COVID-era telemedicine flexibilities, which had allowed practitioners to prescribe controlled substances via telehealth without any in-person visit.
Rather than let the flexibilities lapse immediately, DEA issued a series of temporary extensions. As of January 1, 2026, the Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities is in effect through December 31, 2026. This means:
- DEA-registered practitioners — including NPs with their own DEA registration — may prescribe Schedule II–V controlled substances via telemedicine to patients without a prior in-person evaluation
- Audio-video telehealth is permitted for all schedules under the extension
- Audio-only telehealth is permitted for Schedule III–V narcotic medications approved for opioid use disorder (primarily buprenorphine)
- Practitioners must meet the full requirements of their state NP scope of practice laws and collaborative practice agreements where applicable
This extension applies to both existing patients and new patients. The key requirements are that the NP must be validly DEA-registered, must be licensed in the state where the patient is located, and must comply with all applicable state telehealth prescribing rules.
Important caveat: These are temporary extensions. The fourth extension runs through the end of 2026. Whether a fifth extension, a permanent rule, or the finalization of the Special Registration process follows is uncertain as of mid-2026. If you are building a telehealth practice around controlled substance prescribing, build in a contingency plan for what happens when the extension expires.
DEA Special Registration: proposed but not finalized
In January 2025, the DEA published a proposed rule that would create a formal Special Registration framework — a permanent mechanism allowing practitioners to prescribe controlled substances via telemedicine without a prior in-person visit, subject to additional requirements. Three types of special registrations were proposed:
- A telemedicine prescribing registration for individual practitioners
- A platform registration for online platforms that facilitate prescribing
- A registration for treatment programs
As of mid-2026, the Trump administration has not finalized this proposed rule. The fourth temporary extension is filling the gap. NPs should monitor DEA rulemaking activity for finalization, which would establish more permanent operating parameters.
Schedule differences: II vs. III–V in telehealth
The distinction between DEA Schedule II and Schedules III–V matters in telehealth, though the 2026 extension has narrowed the practical difference under federal law.
| Schedule | Examples | Telehealth prescribing under 2026 extension |
|---|---|---|
| Schedule II | Amphetamines (Adderall, Vyvanse), methylphenidate, oxycodone, fentanyl, morphine | Permitted via audio-video telehealth |
| Schedule III | Buprenorphine, testosterone, ketamine, some codeine formulations | Permitted via audio-video; buprenorphine also permitted audio-only for OUD |
| Schedule IV | Benzodiazepines (Xanax, Ativan, Klonopin), zolpidem, tramadol | Permitted via audio-video telehealth |
| Schedule V | Low-dose codeine cough products, pregabalin | Permitted via audio-video telehealth |
Under federal law as extended, there is no absolute prohibition on prescribing any of these via telehealth in 2026. The substantive restrictions now come primarily from state law.
State-level restrictions: where it gets complicated
Federal law sets the floor. State law can raise it considerably higher. Several categories of state restrictions matter for telehealth NPs:
State telehealth prescribing laws: Some states prohibit prescribing Schedule II controlled substances via telehealth regardless of federal flexibility. Others require an in-person evaluation for initial prescriptions even when federal law does not. Check your state’s telehealth practice standards and your state medical or nursing board guidance.
NP scope of practice and prescriptive authority: Even if federal law permits telehealth prescribing, your state NP practice act governs what you can prescribe. In states with restrictive NP practice, your collaborative practice agreement may limit which schedules you can prescribe, require physician co-signature, or restrict telehealth-only prescribing.
State controlled substance laws: Many states have additional requirements for prescribing opioids specifically — mandatory prescription drug monitoring program (PDMP) queries, dosage limits, duration limits, and required counseling. These apply equally to telehealth prescribing.
Prescribing across state lines: You must be licensed in the state where the patient is physically located at the time of the telehealth encounter. If you hold a compact nurse practitioner license under the Nurse Licensure Compact (NLC), check whether your NP prescriptive authority extends across compact states — NP authority under the compact differs from RN authority.
Substances most affected by telehealth rules
Stimulants (ADHD medications): Adderall, Vyvanse, Ritalin, and Concerta are Schedule II. During the COVID extension period, telehealth ADHD prescribing expanded dramatically. Under the 2026 extension, this remains permitted federally — but several states have added state-level restrictions following public concern about telehealth ADHD prescribing volume. Some states now require in-person initial evaluations for new ADHD diagnoses even where federal law does not.
Opioids: Schedule II opioids (oxycodone, hydrocodone combination products, morphine, fentanyl) can be prescribed via telehealth under the 2026 extension, but opioid prescribing is subject to intense scrutiny and has extensive state-level overlay requirements (PDMP, dosing limits, treatment agreements). Chronic opioid management via telehealth remains high-risk from a regulatory standpoint.
Benzodiazepines: Schedule IV. Permitted under the extension. State restrictions vary; some states have concurrent prescribing warnings or require documentation of alternatives attempted before initiating.
Sleep medications: Zolpidem and similar agents are Schedule IV. Permitted via telehealth.
Buprenorphine/Suboxone for OUD: Schedule III. This is the most clearly supported telehealth prescribing scenario. Buprenorphine for opioid use disorder can be prescribed via audio-only telehealth under the extension — no video required — reflecting strong public health policy support for expanding OUD treatment access.
Documentation standards for telehealth controlled substance prescribing
Your documentation must support the clinical necessity of the prescription and demonstrate compliance with applicable rules. For every telehealth controlled substance prescription:
- Document the telehealth modality used (audio-video or audio-only)
- Record the patient’s physical location at the time of the encounter
- Document the clinical evaluation findings that support the prescription
- Record PDMP query results before issuing the prescription
- Document any patient education about risks and safe storage
- Include the diagnosis and clinical rationale
- Note any relevant state-specific requirements you completed (e.g., required counseling, dosing limitation justification)
Telehealth records are subject to the same legal scrutiny as in-person records. A DEA audit of a telehealth practice will focus on whether your documentation supports the prescriptions issued. Thorough documentation is your primary defense.
For your DEA registration requirements, see NP DEA registration.
Practical workflow for telehealth NPs
NPs building telehealth practices around controlled substance prescribing should consider the following structural approach:
- Verify your DEA registration is current and covers the state(s) where your patients are located (DEA registration is practice-location specific)
- Confirm your state NP authority for each controlled substance you intend to prescribe — including whether your collaborative practice agreement, if required, covers those substances
- Query PDMP before every controlled substance prescription — most states require this; many require it for telehealth encounters specifically
- Maintain audio-video capability — audio-only telehealth is only explicitly permitted under the 2026 extension for buprenorphine/OUD; all other schedules should use audio-video to stay within clearly documented extension parameters
- Track the DEA extension status — the fourth extension expires December 31, 2026; build an operational plan for what changes if it is not renewed or if a new rule takes effect
- Document every encounter as if it will be audited — telehealth controlled substance prescribing is a DEA enforcement priority
When to get legal or regulatory help
Consult a healthcare attorney familiar with DEA regulations and NP practice if:
- You are starting a new telehealth practice and are uncertain about your prescriptive authority in the states you plan to serve
- You have received any DEA inquiry related to your telehealth prescribing volume or practices
- You are prescribing across state lines and are unsure whether your licensure covers NP prescriptive authority in compact or non-compact states
- A patient or pharmacy has disputed a telehealth prescription and regulatory review is likely
For billing and reimbursement issues related to telehealth practice, see NP billing and reimbursement basics.